Prostate Cancer | Tumor

CURE’s Clinical Trial Corner: February 2021

February 25th 2021, 2:00pm

Article

Here is a list of some recent trials that launched within the cancer space in February.

A Cancer Survivor Embraces a New Career as a ‘Sit-Down Comedian’

February 21st 2021, 7:00pm

Article

“Did you hear the one about the cancer procedure that went terribly wrong?” “It turned out to be a ‘bi-oopsie!’”

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

February 12th 2021, 8:45pm

Article

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

A Valentine’s Day Miracle for Cancer Survivors

February 12th 2021, 5:00pm

Article

Instead of buying your sweetheart chocolates for Valentine’s Day this year, one cancer survivor suggests people get screened as a gift to their significant other.

Varying Radiation Regimens by Dose, Time Show Similar Long-Term Quality of Life Outcomes in Prostate Cancer

February 3rd 2021, 9:00pm

Article

Patients with prostate cancer experienced no significant difference in quality of life when treated with two different types of radiation regimens, recent research has found.

Nubeqa Improves 3-Year Survival in Nonmetastatic Prostate Cancer

January 26th 2021, 2:00pm

Article

At three years, overall survival in men with nonmetastatic, castration-resistant prostate cancer treated with Nubeqa was 83% compared with 77% in those who received placebo.

Men with Prostate Cancer Experience Higher Levels of Fatigue Due to Inflammation

January 13th 2021, 2:00pm

Article

Men who are receiving androgen deprivation therapy treatment for prostate cancer experience higher levels of fatigue and depression when compared to men who are not receiving treatment and who have no history of cancer.

Lynparza Leads to Longer Survival in Men With Prostate Cancer

January 12th 2021, 10:00pm

Article

Lynparza demonstrates a significantly longer duration of survival compared Xtandi or Zytiga for men with metastatic prostate cancer, one study found.

Mediterranean Diet Adherence Lowers Disease Progression in Low-Risk Prostate Cancer

January 12th 2021, 4:00pm

Article

Researchers observed the benefit of adhering to a Mediterranean diet in all men, in addition to non-White men and those without diabetes.

Talking about Our Family Cancer Risk With My Son

January 9th 2021, 8:00pm

Article

Generations of cancer leads to the risk that must be addressed head-on, but the lessons we can take from our own family members who have had cancer is valuable to pass on.